When.com Web Search

Search results

  1. Results From The WOW.Com Content Network
  2. Faricimab - Wikipedia

    en.wikipedia.org/wiki/Faricimab

    Faricimab, sold under the brand name Vabysmo (/ v ə ˈ b aɪ z m oʊ / və-BYEZ-mow), is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).

  3. List of therapeutic monoclonal antibodies - Wikipedia

    en.wikipedia.org/wiki/List_of_therapeutic...

    chronic graft-versus-host disease: Azintuxizumab vedotin [28] mab: chimeric/ humanized: CD319: cancer Bamlanivimab [29] mab: human: spike protein receptor binding domain (RBD) of SARS-CoV-2: US emergency use authorization (EUA) when used with etesevimab [30] COVID-19: Bapineuzumab [31] mab: humanized: β-amyloid: Alzheimer's disease ...

  4. FDA Approves First Injectable Eye Medicine For Vision Loss ...

    www.aol.com/news/fda-approves-first-injectable...

    Vabysmo is the first and only FDA-approved injectable eye medicine for wet AMD and DME that improves and. The FDA has approved Genentech's, a unit of Roche Holdings AG (OTC: RHHBY), Vabysmo ...

  5. Bevacizumab - Wikipedia

    en.wikipedia.org/wiki/Bevacizumab

    Bevacizumab, sold under the brand name Avastin among others, is a monoclonal antibody medication used to treat a number of types of cancers and a specific eye disease. [30] [28] For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, ovarian cancer, glioblastoma, hepatocellular carcinoma, and renal-cell carcinoma. [31]

  6. Roche shares fall on modest 2024 outlook - AOL

    www.aol.com/news/roche-forecasts-return-growth...

    Roche is banking on new drug Vabysmo, which is used to treat a common form of blindness in the elderly and which won approval in 2022, to drive short-term growth and said on Thursday the drug had ...

  7. Brolucizumab - Wikipedia

    en.wikipedia.org/wiki/Brolucizumab

    Brolucizumab is approved by the US Food and Drug Administration (FDA) for use in ophthalmology. [7] [8]Brolucizumab successfully completed phase III development in wet age-related macular degeneration (AMD) meeting the primary efficacy endpoint of non-inferiority to aflibercept in mean change in best corrected visual acuity (BCVA) from baseline to week 48.

  8. Anti-VEGF - Wikipedia

    en.wikipedia.org/wiki/Anti-VEGF

    By May 2012, anti-VEGF treatment with Avastin has been accepted by Medicare, is quite reasonably priced, and effective. Lucentis has a similar but smaller molecular structure to Avastin, and is FDA-approved (2006) for treating MacD, yet remains more costly, as is the more recent (approved in 2011) aflibercept (Eylea). Tests on these treatments ...

  9. List of drugs: V–Ve - Wikipedia

    en.wikipedia.org/wiki/List_of_drugs:_V–Ve

    This multi-page article lists pharmaceutical drugs alphabetically by name. Many drugs have more than one name and, therefore, the same drug may be listed more than once. ...